Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline

By: via Benzinga
The hepatitis C industry has been on fire since Merck (NYSE: MRK) paid a 230 percent premium for pharmaceutical company Idenix (NASDAQ: ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.